The acetylcholinesterase inhibitor rivastigmine does not alter total choices for methamphetamine, but may reduce positive subjective effects, in a laboratory model of intravenous self-administration in human volunteers.
about
Pharmacotherapy for stimulant-related disordersPharmacotherapy of amphetamine-type stimulant dependence: an updateCognitive enhancement as a pharmacotherapy target for stimulant addictionEvaluation of modafinil effects on cardiovascular, subjective, and reinforcing effects of methamphetamine in methamphetamine-dependent volunteers.Pharmacological approaches to methamphetamine dependence: a focused review.Cognitive enhancers in the treatment of substance use disorders: clinical evidence.Cholinergic modulation of food and drug satiety and withdrawal.Safety and efficacy of varenicline to reduce positive subjective effects produced by methamphetamine in methamphetamine-dependent volunteersPreliminary findings of the effects of rivastigmine, an acetylcholinesterase inhibitor, on working memory in cocaine-dependent volunteersContribution of both M1 and M4 receptors to muscarinic agonist-mediated attenuation of the cocaine discriminative stimulus in mice.The effects of varenicline on methamphetamine self-administration and drug-primed reinstatement in female rats.Safety and Preliminary Efficacy of the Acetylcholinesterase Inhibitor Huperzine A as a Treatment for Cocaine Use DisorderEvaluation of the cardiovascular and subjective effects of rivastigmine in combination with methamphetamine in methamphetamine-dependent human volunteersNovel medications to treat addictive disordersSex differences in the neural mechanisms mediating addiction: a new synthesis and hypothesisDiscriminative stimulus and subject-rated effects of methamphetamine, d-amphetamine, methylphenidate, and triazolam in methamphetamine-trained humans.Rivastigmine reduces "Likely to use methamphetamine" in methamphetamine-dependent volunteers.Cholinergic functioning in stimulant addiction: implications for medications development.Acute and chronic effects of the M1/M4-preferring muscarinic agonist xanomeline on cocaine vs. food choice in rats.Muscarinic receptors: their roles in disorders of the central nervous system and potential as therapeutic targets.Epidemiological trends and the advances of treatments of amphetamine-type stimulants (ATS) in China.A threshold model for opposing actions of acetylcholine on reward behavior: Molecular mechanisms and implications for treatment of substance abuse disorders.Chronic methamphetamine self-administration disrupts cortical control of cognition.Acetylcholine, drug reward and substance use disorder treatment: intra- and interindividual striatal and accumbal neuron ensemble heterogeneity may explain apparent discrepant findings.Pilot safety evaluation of varenicline for the treatment of methamphetamine dependence.Reversal of cocaine-conditioned place preference and mesocorticolimbic Zif268 expression by social interaction in rats.The effects of varenicline on methamphetamine self-administration and drug-primed reinstatement in male rats.Acquisition and reinstatement of ethanol-induced conditioned place preference in rats: Effects of the cholinesterase inhibitors donepezil and rivastigmine.
P2860
Q26829186-7B284F34-4F50-4122-998E-A4B922089315Q26991936-CEDFD636-7205-4712-972C-753144D2BF4FQ33599983-5590543A-7A4B-40DB-A8B9-E410CF72643DQ33625390-78B4E991-D16E-4B19-8C33-0A7A1C6889C4Q33906303-1058E4A5-AA44-4EBA-8F07-1E544C28EE3EQ34183988-28A564E8-AA94-44D6-8B84-3590295B1284Q35180592-0600B203-92E6-4BE3-A559-CEC08CD3DC1AQ35580343-40D25B1A-FE2F-4158-A047-E20F5B352F44Q35609711-6EA6657D-A073-439B-B424-362BE387CA54Q35857172-409A7182-CDCD-459A-8CB2-01D68B379A1BQ36494806-D945AFF4-3F34-45E8-8329-790ED1929DA4Q36749831-73ED2491-3B18-43C6-9AA2-10D4CEE5A64BQ36968973-A8747D8E-3BA2-446E-9FB4-A358FCB8CE21Q37029633-8CE40C39-8419-4FF0-98AB-16C797530153Q37047922-F54F8CEB-5007-49C4-BACA-FE23EF65D89EQ37192699-A2C142BE-0B82-4F62-B100-DC60016B222EQ37425104-B2A02728-365F-4B79-AA6A-AFBBF4AFF130Q37618780-59B5CB9F-1755-4A4C-9A54-769AFA731F16Q37625841-E4C078A5-E561-45B8-B89C-0DF803046FFDQ37954379-BF73419A-0BA0-4371-B2F1-89DB394EE4C8Q38203929-32B36D1F-4767-4464-863F-D537C2ADBE3CQ38851564-A0C650FF-4CC2-45CE-9C1E-68ECC30CC451Q38906406-9E61617A-AE78-4B92-A490-9D2A9C2CDC91Q42513387-2F3347F8-61AE-4A1B-8956-C43883023680Q42583506-BB570FC0-7B7A-44A7-91FB-7DA6840269EEQ48154452-E1C5F761-CCC1-42FF-B955-BCFDB787287CQ48400058-71D723C2-5FDF-4A2B-9246-8F92D07B05B9Q50518972-32D8709E-3F8D-47CC-91CC-C8E85032DCDB
P2860
The acetylcholinesterase inhibitor rivastigmine does not alter total choices for methamphetamine, but may reduce positive subjective effects, in a laboratory model of intravenous self-administration in human volunteers.
description
2008 nî lūn-bûn
@nan
2008 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
The acetylcholinesterase inhib ...... istration in human volunteers.
@ast
The acetylcholinesterase inhib ...... istration in human volunteers.
@en
The acetylcholinesterase inhib ...... istration in human volunteers.
@nl
type
label
The acetylcholinesterase inhib ...... istration in human volunteers.
@ast
The acetylcholinesterase inhib ...... istration in human volunteers.
@en
The acetylcholinesterase inhib ...... istration in human volunteers.
@nl
prefLabel
The acetylcholinesterase inhib ...... istration in human volunteers.
@ast
The acetylcholinesterase inhib ...... istration in human volunteers.
@en
The acetylcholinesterase inhib ...... istration in human volunteers.
@nl
P2860
P50
P1476
The acetylcholinesterase inhib ...... nistration in human volunteers
@en
P2093
C Culbertson
P2860
P304
P356
10.1016/J.PBB.2007.12.010
P407
P577
2008-01-22T00:00:00Z